Track record · closed signal

Pfizer Inc (PFE) — closed signal from March 17, 2026

Partial Published before the outcome was known, scored automatically when the window closed on June 15, 2026 — -4.5% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$26.60 – $27.40Entry zone — fair-value band

$27.23Published — price the day we called it

$29.41Target — the price the thesis aimed for

$28.75Peak — highest point inside the window, not a realized return

$26.00Window close — end-of-window price, context only

What happened

Partial

Reached 69% of the predicted growth at its peak, without hitting the target.

At window close

-4.5%

realized, from the publication price to the last close inside the window

Peak gain

+5.5%

peak, from the publication price — not a realized return

S&P 500, same window

+12.8%

SPY over the identical days, dividend-adjusted

Window close

$26.00

last close inside the window, ended June 15, 2026

Peak price

$28.75

peak on April 2, 2026 — not a realized return

Days to target

—

The thesis — published March 17, 2026

Predicted growth

+8%

over the measurement window

Target price

$29.41

the price the thesis aimed for

Entry zone

$26.60 – $27.40

the fair-value band we waited for

Price at publication

$27.23

published March 17, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer is worth watching mainly because it acts like a safer investment and has a recent positive drug trial to focus on. That trial gives the stock a specific reason to move, but the company's overall business has mixed signs, so this is likely a modest bounce rather than a big, sustained move. Expect steady, cautious gains short term.

Primary drivers

Good drug trial news creates a near-term reason to buy
Low volatility makes the stock feel safer in downturns
Earnings have been relatively steady lately
Looks like a chance to buy on a modest rebound

How it played out

PFE: 5.5% peak gain fell short of the target

Lyra published PFE at $27.23 with an 8% short-term growth expectation and a $29.41 target. The thesis expected a modest, cautious rebound. It pointed to positive drug trial news, low volatility during downturns, relatively steady earnings, and a possible rebound from the entry zone.

PFE rose to a $28.75 peak on April 2, a 5.5% gain, but it stayed below the target throughout the window. By June 15, it had fallen to $26, below the published price and the $26.60 to $27.40 entry zone. The thesis partially played out because the stock rose at first, but the expected 8% gain never arrived and the window ended lower.

What happened during the window

On May 5, Pfizer reported first-quarter results and reaffirmed its full-year guidance. On May 28, Pfizer and Innovent Biologics announced a global licensing and collaboration agreement covering 12 cancer medicine programs.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals